FLOW Trial: Semaglutide and 24% Fewer Kidney Events The first dedicated GLP-1 kidney-outcomes trial in type 2 diabetes and CKD. d. 2026;4(20):40-41. Accessed July 28, 2026. https://thediabzen.com/index.php/d/article/view/63